BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

arGentis Pharmaceuticals, LLC 

896 Stone Hedge Cove

Collierville  Tennessee  38017-7379  U.S.A.
Phone: 901-448-1580 Fax: n/a


SEARCH JOBS








 Company News
arGentis Pharmaceuticals, LLC Acquires Rights to Rheumatoid Arthritis Therapy Entering Phase I Clinical Trial; Partnering with University of Tennessee And Veterans Affairs Medical Center 11/12/2009 9:25:08 AM    More...
arGentis Pharmaceuticals, LLC Expands Scientific Advisory Board 10/16/2009 8:16:11 AM    More...
arGentis Pharmaceuticals, LLC Receives Orphan Drug Designation for European Union 2/17/2009 9:50:57 AM    More...
arGentis Pharmaceuticals, LLC Receives Favorable Opinion for European Orphan Drug Designation 1/6/2009 8:47:22 AM    More...
arGentis Pharmaceuticals, LLC Presents at Southeast BIO (SEBIO) 10th Annual Investor Forum 12/10/2008 9:14:21 AM    More...
arGentis Pharmaceuticals, LLC Files Patent on Nucleic Acid Sequences and Polymorphisms Predictive of Patient Responses to ARG201 an Immunotherapy for Late Phase Systemic Sclerosis 7/1/2008 10:24:46 AM    More...
arGentis Pharmaceuticals, LLC Release: Phase II Results for Low-Dose Oral Immune Tolerance Therapy (ARG201) in Systemic Scleroderma Published 6/30/2008 9:13:18 AM    More...
arGentis Pharmaceuticals, LLC Licenses Third Treatment for Dry Eye Syndrome 5/12/2008 10:24:21 AM    More...
Innova Memphis Inc. Invests In arGentis Pharmaceuticals, LLC 4/21/2008 8:45:48 AM    More...
arGentis Pharmaceuticals, LLC Receives Orphan Drug Designation 2/8/2008 7:49:21 AM    More...
12

//-->